Hospitals are increasingly struggling to obtain essential chemotherapy drugs, a situation experts attribute to a fragile U.S. drug supply chain heavily dependent on foreign manufacturers, particularly in China and India. The United States relies on these countries for a significant portion of the key starting materials used in drug production.
According to supply-chain monitoring data, 41% of a drug's essential ingredients originate solely from China. This concentration creates a vulnerability, as disruptions in production or export from these nations can directly impact the availability of critical medications in the U.S. and globally.
Current market dynamics incentivize hospitals to prioritize the cheapest upfront cost for drugs, a system that fails to ensure supply chain resilience. "There's no real mechanism for hospitals to pay more to ensure greater resilience," noted one expert. The consistent and reliable manufacturing of essential medicines, which should be both affordable and high-quality, is not being met by existing market structures.
In response to such vulnerabilities, some U.S. health systems have explored alternative manufacturing models. One such initiative is Civica, a non-profit drug manufacturer established in 2018. Based in Petersburg, Virginia, Civica aims to ensure a consistent supply of certain generic drugs at a sustainable cost through domestic production. However, its current manufacturing portfolio does not include chemotherapy drugs.
Another organization, Phlow Pharmaceuticals, was founded in 2020 with a mission to produce active pharmaceutical ingredients within the U.S., aiming to reduce the nation's reliance on overseas sources for these critical components.